●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results fo ...

SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first qu ...

Core Viewpoint - Veracyte (VCYT) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance and Outlook - The upgrade indicates an improvement in Veracyte's underlying business, which is expected to positively influence its stock price [5]. - Veracyte is projected to earn $1.20 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 0.8% [8]. Analyst Sentiment and Consensus - Over the past three months, the Zacks Consensus Estimate for Veracyte has increased by 10.6%, indicating a positive trend in analyst sentiment [8]. - The Zacks rating system maintains a balanced approach, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, highlighting Veracyte's strong position in earnings estimate revisions [9][10].

Qiagen (QGEN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. I'm Lisa, your PGI call operator. Welcome, and thank you for joining QIAGEN's Q1 twenty twenty five Earnings Conference Call Webcast. At this time, all participants are in a listen only mode. Please be advised that this call is being recorded at QIAGEN's request and will be made available on their Internet site. The prepared remarks will be followed by a question and answer session. At this ...

Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and is targeting revenues of C$ 2.0 million per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4] Financial Results Announcement - Microbix plans to file its financial statements and results for the second quarter of fiscal 2025, which ended on March 31, 2025, before trading starts on May 15, 2025 [1] - A webinar discussion regarding the Q2 2025 results will be held at 11:00 AM ET on the same day, featuring the CEO, CFO, and COO [1] Webinar Participation - Investors and shareholders can participate in the webinar hosted by Adelaide Capital by registering online [2] - The webinar will also be live-streamed on YouTube, and a replay will be available on Adelaide Capital's YouTube channel [2][3] Product and Market Reach - Microbix's antigens are utilized by approximately 100 diagnostics manufacturers, and its QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The QAPs are available in over 30 countries, supported by a network of international distributors [4] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [4]

Financial Data and Key Metrics Changes - Total reported revenue for Q1 2025 was $693 million, down from $711 million in the prior year, primarily due to lower COVID and donor screening revenue [18] - Excluding COVID and donor screening, the company achieved a mid single-digit revenue growth of 6% [18] - Adjusted EBITDA margin improved by 450 basis points year over year to 23%, with adjusted diluted EPS increasing by 68% to $0.74 [24][25] Business Line Data and Key Metrics Changes - Labs business, accounting for 54% of total revenue, grew by 7%, driven by clinical chemistry and immunoassay testing [10] - Immunohematology business grew by 4%, maintaining its global leadership position [10] - Point of Care business represented 25% of Q1 revenue and grew by 8% excluding COVID, with strong flu sales leading to an 18% year-over-year growth [10] - Molecular Diagnostics business grew by 11% excluding COVID, with ongoing clinical trials for the Savanna respiratory panel [11] Market Data and Key Metrics Changes - Revenue from the "Other" region (Japan, Asia Pacific, Latin America) grew by 12%, driven by a 17% increase in Labs revenue [19] - North America revenue declined by 6% due to lower COVID revenue and donor screening wind down, but grew by 5% when excluding these factors [19] - Europe, Middle East, and Africa grew by 9%, while China revenue remained flat, primarily due to order timing and decreased Triage revenue [20] Company Strategy and Development Direction - The company is focused on a narrow set of strategic initiatives, including increasing platform content and utility, expanding margins, and enhancing commercial execution [11] - Plans to realize $100 million in annualized cost savings, with $50 million expected in the first half of 2025 [12] - The company aims to maintain its manufacturing footprint and continue investing in U.S.-based manufacturing and R&D [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and operational discipline, highlighting strong Q1 results and ongoing initiatives [9] - The company anticipates potential tariff impacts of $30 million to $40 million in 2025 but believes mitigation plans will offset these impacts [15] - Full-year 2025 financial guidance remains unchanged, with expectations for total reported revenue between $2.6 billion and $2.81 billion [27] Other Important Information - The company has invested nearly $1 billion in U.S.-based manufacturing and R&D over the past three years [13] - Adjusted free cash flow for Q1 2025 was $47 million, representing 29% of adjusted EBITDA [26] - The company plans to refinance its debt in the second half of 2025 or early 2026, depending on market conditions [31] Q&A Session Summary Question: Can you elaborate on the tariff impact and pricing actions? - Management indicated that selective pricing actions are being considered to offset tariff impacts, but competitive market conditions must be taken into account [36][37] Question: Will tariff impacts affect long-term manufacturing plans? - Management does not expect changes to the overall manufacturing footprint, emphasizing the importance of their global manufacturing network [38] Question: How confident is the company in mitigating tariff impacts? - Management expressed confidence in fully mitigating tariff impacts through various actions, including cost reductions and realigning inventories [43] Question: What underpins the confidence in China's growth rate? - Confidence in mid to high single-digit growth in China is based on strong performance in labs and immunohematology, despite some softness in Triage sales [49] Question: What is the status of the Savanna program? - The company is focused on completing the RBP4x submission to the FDA and is not speculating on outcomes beyond that [45][61] Question: How is the respiratory sales performance impacting guidance? - Management expects to maintain the guidance range for COVID revenue despite a decline, as flu sales have been strong [56][58]

OraSure (OSUR) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Jason Plagman - VP - Investor RelationsCarrie Manner - President & Chief Executive OfficerKenneth McGrath - Chief Financial OfficerNoah Lewis - Equity Research Associate Conference Call Participants None - Analyst Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. Twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After ...

Veracyte (VCYT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Shayla Gorman - Senior Director - Investor RelationsMarc Stapley - CEORebecca Chambers - CFOSubbu Nambi - Managing DirectorJohn Leite - Global CCOPuneet Souda - Senior MDColleen Babington - Equity Research AssociateThomas DeBourcy - Principal Conference Call Participants Andrew Brackmann - Equity Research AnalystTejas Savant - Executive Director & Senior Healthcare Equity AnalystSung Ji Nam - Managing Director, Senior Equity ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $114.5 million, representing an 18% year-over-year growth, driven by testing revenue growth of 19% year-over-year [5][28] - Adjusted EBITDA margin was 21.6%, significantly higher than expected, with a strong balance sheet of $287 million in cash and short-term investments [5][28] - Non-GAAP gross margin was 72%, up approximately 400 basis points year-over-year, while testing gross margin was 74%, up approximately 200 basis points [30][32] Business Line Data and Key Metrics Changes - Decipher testing revenue grew by 33% year-over-year, with volume growth of 37%, totaling approximately 22,600 tests [6][28] - Afirma testing volume increased by 10% year-over-year, resulting in approximately 15,500 tests, but revenue growth was lower due to prior period collection benefits [12][28] - Product line revenue was $3.6 million, up 1% year-over-year, while biopharmaceutical and other revenue was also $3.6 million, up 19% year-over-year [29] Market Data and Key Metrics Changes - The company reported a record number of ordering providers for Decipher, up over 20% from the prior year, indicating strong market penetration [6][28] - The Decipher prostate metastatic test is expected to launch broadly in June 2025, expanding the population eligible for testing [9][10] - The MRD platform is advancing with a focus on muscle invasive bladder cancer, with commercial launch expected in the first half of 2026 [18][19] Company Strategy and Development Direction - The company is focused on expanding its existing tests, Decipher and Afirma, and launching new products like Prosigna in the U.S. breast cancer market [16][17] - Strategic initiatives include international expansion and addressing novel cancer challenges with innovative products [6][25] - The company aims to leverage its Veracyte Diagnostics platform to generate clinical evidence and support product adoption [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong growth despite a challenging macro environment, citing positive trends in testing volume and provider engagement [5][6] - The company reiterated its 2025 testing revenue guidance of $470 million to $480 million, raising adjusted EBITDA margin guidance to 22.5% [33][34] - Management emphasized the importance of evidence generation and reimbursement for new product launches, ensuring organizational readiness for upcoming launches [48][52] Other Important Information - The company is undergoing a bankruptcy process for its French subsidiary, Veracyte SAS, which will not impact its overall strategy or revenue models for the next five years [21][24] - The launch of the Prosigna LDT is expected to begin in mid-2026, targeting a significant market of over 300,000 breast cancer patients annually in the U.S. [16][17] Q&A Session Summary Question: Thoughts on portfolio optimization and pipeline value of MRD and nasal swab - Management is focused on portfolio management, ensuring investments have appropriate evidence and reimbursement, and is excited about the broad pipeline of new products [37][40] - The MRD and nasal swab initiatives are seen as having significant market potential, with upcoming milestones expected to validate their value [42][43] Question: Organizational readiness for upcoming product launches - The company has a thoughtful launch plan in place, ensuring that investments are made in line with growth opportunities and that commercial activities are well-prepared [48][52] Question: Clarification on guidance and growth expectations for Afirma - Afirma is expected to see high single-digit revenue growth for the year, with volume growth driven by prior period collections and market dynamics [66][67] Question: Differentiation of Prosigna in a competitive market - Management believes Prosigna is differentiated based on evidence generation and a strong playbook similar to Decipher, aiming to gain market share in the U.S. [73][75]

Company Announcement - Oncocyte Corp. will report its first quarter 2025 financial results after the market closes on May 12, 2025 [1] - A live Zoom webinar will be held at 2:00 p.m. PT on the same day to discuss the financial results [1][2] Investor Information - The webinar will include a Q&A session and requires registration for access [2] - An archived replay of the webinar will be available on Oncocyte's investor relations website after the call concludes [2] Company Overview - Oncocyte is a diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to enhance patient outcomes [3]